

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)



(10) International Publication Number
WO 2022/123307 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) *C07K 14/725* (2006.01)
A61K 39/00 (2006.01) *C07K 16/40* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2021/000852

(22) International Filing Date:

09 December 2021 (09.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/123,333 09 December 2020 (09.12.2020) US

(71) Applicants: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, 5410045 (JP). **CRESCENDO BIOLOGICS LTD** [GB/GB]; Meditrina Building 260, Babraham Research Campus, Cambridge CB22 3AT (GB).

(72) Inventors: **SHAPIRO, Gary**; c/o Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA 02139 (US). **HE, Xingyue**; c/o Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA 02139 (US). **NG, Mei, Rosa**; c/o Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA 02139 (US). **THOMPSON, Lorraine**; c/o Crescendo Biologics Ltd, Meditrina Building 260, Babraham Research Campus, Cambridge

CB22 3AT (GB). **FRANCO, Elena, De Juan**; c/o Crescendo Biologics Ltd, Meditrina Building 260, Babraham Research Campus, Cambridge CB22 3AT (GB). **VANCE, Steven**; c/o Crescendo Biologics Ltd, Meditrina Building 260, Babraham Research Campus, Cambridge CB22 3AT (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF



FIG. 1A




FIG. 1B

(57) Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules provided herein.

[Continued on next page]

WO 2022/123307 A1

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*